Advanced search
Publication Cover
Leukemia & Lymphoma Volume 52, 2011 - Issue sup2
Submit an article Journal homepage
900
Views
52
CrossRef citations to date
0
Altmetric
Articles

Long-term results for pentostatin and cladribine treatment of hairy cell leukemia

Claire E. DeardenThe Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, UKCorrespondence[email protected]
,
Monica ElseThe Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, UK
&
Daniel CatovskyThe Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, UK
Pages 21-24 | Published online: 23 May 2011

Citations (52)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Mehdi Dehghani, Ali Kashkooe, Nasrin Namdari, Reza Majidi, Mojtaba Karimi, Shirin Haghighat, Alireza Rezvani & Negar Safari. (2023) Long-term follow-up of patients with hairy cell leukemia in the south of Iran. Expert Review of Hematology 16:4, pages 289-295.
Read now
Tadeusz Robak & Paweł Robak. (2023) Refractory and relapsed hairy-cell leukemia (HCL): casting light on promising experimental drugs in clinical trials. Expert Opinion on Investigational Drugs 32:4, pages 311-324.
Read now
Agnieszka Janus & Tadeusz Robak. (2019) Moxetumomab pasudotox for the treatment of hairy cell leukemia. Expert Opinion on Biological Therapy 19:6, pages 501-508.
Read now
Montserrat López-Rubio & Jose Antonio Garcia-Marco. (2015) Current and emerging treatment options for hairy cell leukemia. OncoTargets and Therapy 8, pages 2147-2156.
Read now
Tadeusz Robak, Anna Wolska & Pawel Robak. (2015) Potential breakthroughs with investigational drugs for hairy cell leukemia. Expert Opinion on Investigational Drugs 24:11, pages 1419-1431.
Read now

Articles from other publishers (47)

Diana Cenariu, Ioana Rus, Jon Thor Bergthorsson, Ravnit Grewal, Mihai Cenariu, Victor Greiff, Adrian-Bogdan Tigu, Delia Dima, Cristina Selicean, Bobe Petrushev, Mihnea Zdrenghea, Jonathan Fromm, Carmen-Mariana Aanei & Ciprian Tomuleasa. (2023) Flow Cytometry of CD5-Positive Hairy Cell Leukemia. Molecular Diagnosis & Therapy 27:5, pages 593-599.
Crossref
Tuba ERSAL, Fahir ÖZKALEMKAŞ, Vildan OZKOCAMAN, İbrahim Ethem PINAR, Cumali YALÇIN, Bedrettin ORHAN, Ömer CANDAR, Sinem ÇUBUKÇU, Tuba GÜLLÜ KOCA & Rıdvan ALİ. (2023) Subcutaneous and Intravenous Cladribine Treatment of Hairy Cell Leukemia Patients: Do We Still Need Intravenous Cladribine?. Turkish Journal of Internal Medicine 5:2, pages 109-116.
Crossref
Shahan Tariq, Muhammad Ammar Bin Hamid, Nazia Rahman, Lindsey Oleary, Kristine Wong & Aasim Sehbai. (2023) Unusual presentation of gastric cancer during treatment of hairy cell leukemia: Exploring the etiological basis of this rare phenomenon. Cancer Pathogenesis and Therapy 1:2, pages 146-148.
Crossref
Robert J. Kreitman, Philippe Moreau, Farhad Ravandi, Martin Hutchings, Anas Gazzah, Anne-Sophie Michallet, Zev A. Wainberg, Alexander Stein, Sascha Dietrich, Maja J. A. de Jonge, Wolfgang Willenbacher, Jacques De Grève, Evgeny Arons, Palanichamy Ilankumaran, Paul Burgess, Eduard Gasal & Vivek Subbiah. (2023) Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia . Blood 141:9, pages 996-1006.
Crossref
Farhad Ravandi, Robert J. Kreitman, Enrico Tiacci, Leslie Andritsos, Versha Banerji, Jacqueline C. Barrientos, Seema A. Bhat, James S. Blachly, Alessandro Broccoli, Timothy Call, Dai Chihara, Claire Dearden, Judit Demeter, Sasha Dietrich, Monica Else, Narendranath Epperla, Brunangelo Falini, Francesco Forconi, Douglas E. Gladstone, Alessandro Gozzetti, Sunil Iyengar, James B. Johnston, Jeffrey Jorgensen, Gunnar Juliusson, Francesco Lauria, Gerard Lozanski, Sameer A. Parikh, Jae H. Park, Aaron Polliack, Graeme Quest, Tadeusz Robak, Kerry A. Rogers, Alan Saven, John F. Seymour, Tamar Tadmor, Martin S. Tallman, Constantine S. Tam, Philip A. Thompson, Xavier Troussard, Clive S. Zent, Thorsten Zenz, Pier Luigi Zinzani, Bernhard Wörmann, Kanti Rai & Michael Grever. (2022) Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer Journal 12:12.
Crossref
Jérôme Paillassa & Xavier Troussard. (2021) Patients with relapsed/refractory hairy‐cell leukemia. Cancer Reports 5:3.
Crossref
Xavier Troussard, Elsa Maître & Edouard Cornet. (2021) Hairy cell leukemia 2022: Update on diagnosis, risk‐stratification, and treatment. American Journal of Hematology 97:2, pages 226-236.
Crossref
L.S. Al-Radi, Svetlana Yurevna Smirnova, T.N. Moiseeva, I.S. Piskunova, L.V. Plastinina, D.V. Novikova, E.G. Gemdzhian & G.M. Galstyan. (2022) Experience with the Use of B-RAF Inhibitor Vemurafenib in the Treatment of Hairy Cell Leukemia. Clinical oncohematology 15:4, pages 349-355.
Crossref
Martina Sollini, Francesco Bartoli, Sara Galimberti, Roberto Boni & Paola A. Erba. 2020. Nuclear Oncology. Nuclear Oncology 1 52 .
Martina Sollini, Francesco Bartoli, Sara Galimberti, Roberto Boni & Paola A. Erba. 2022. Nuclear Oncology. Nuclear Oncology 1329 1380 .
Raheel Siddiqui, Muhammad Sardar, Moazzam Shahzad, Jemin Jose, Insija Selene, Zunaira Shah, Anum Qureshi, Madeeha Shafqat, Rimsha Kashif, Maheen Ahmad, Alex Mejia-Garcia & Faiz Anwer. (2021) Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies. Clinical Lymphoma Myeloma and Leukemia 21:10, pages 659-666.
Crossref
Aybüke OLGUN, Yasemin BAŞBINAR, İnci ALACACIOĞLU, Şerife SOLMAZ, Mahdi AKBARPOUR, Tuğba UYSAL KILIÇ, Özlem KILIÇ, Sermin ÖZKAL, Hülya ELLİDOKUZ & Mehmet Ali ÖZCAN. (2021) B-RAF V600E AND B-RAF CODON 464-469 MUTATIONS IN HAIRY CELL LEUKEMIA PATIENTS AND THEIR RELATION WITH CLINICAL PARAMETERS. Journal of Basic and Clinical Health Sciences 5:3, pages 1-6.
Crossref
Kerry A. Rogers, Leslie A. Andritsos, Lai Wei, Eric M. McLaughlinAmy S. Ruppert, Mirela Anghelina, James S. Blachly, Timothy CallDai Chihara, Anees Dauki, Ling GuoS. Percy Ivy, Lacey R. JamesDaniel JonesRobert J. KreitmanGerard LozanskiDavid M. Lucas, Apollinaire Ngankeu, Mitch Phelps, Farhad RavandiCharles A. Schiffer, William E. CarsonIIIIII, Jeffrey A. Jones & Michael R. Grever. (2021) Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. Blood 137:25, pages 3473-3483.
Crossref
Rikhia Chakraborty, Omar Abdel-Wahab & Benjamin H. Durham. (2021) MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular Age. Cold Spring Harbor Perspectives in Medicine 11:5, pages a034892.
Crossref
Ewa Robak, Dorota Jesionek-Kupnicka & Tadeusz Robak. (2020) Skin changes in hairy cell leukemia. Annals of Hematology 100:3, pages 615-625.
Crossref
Sydney M Fasulo, Spandana Narvaneni, Vinod Kumar, Anusha Manje Gowda & Yasmeen Sultana. (2021) Lytic Bone Lesion: An Unusual Presentation of Hairy Cell Leukemia. Cureus.
Crossref
Nilima Parry‐Jones, Anurag Joshi, Francesco Forconi & Claire Dearden. (2020) Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL‐V). British Journal of Haematology 191:5, pages 730-737.
Crossref
Claire Dearden & Sunil Iyengar. (2020) Hairy Cell Leukaemia: From Hairy Beginnings to a BRAF New World. British Journal of Haematology 191:4, pages 527-534.
Crossref
Rudolf Benz, Kornelius ArnMartin Andres, Thomas PabstMichael BaumannUrban Novak, Felicitas HitzUrs HessReinhard ZenhaeusernYves Chalandon, Ulrich MeySabine Blum, Daniel RauchAlix O'Meara SternNathan CantoniMario BargetziElena Bianchi-PapinaDavide RossiJakob Passweg, Andreas LohriSimona Berardi, Qiyu Li, Anita Feller & Georg Stussi. (2020) Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. Blood Advances 4:15, pages 3699-3707.
Crossref
Alice Boilève, Adrien Contejean, Sylvain Barreau, Élise Sourdeau, Chloé Friedrich, Olivier Kosmider, Barbara Burroni, Nicolas Dupin, Coralie Lheure, Julien Rossignol, Didier Bouscary & Éric Grignano. (2020) Mastocytosis onset in a patient with treated hairy cell leukemia: Just a coincidence?. Blood Cells, Molecules, and Diseases 81, pages 102392.
Crossref
Mark B. Geyer, Omar Abdel-Wahab, Martin S. Tallman & Jae H. Park. 2020. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology 1872 1883.e5 .
Elsa Maitre, Edouard Cornet & Xavier Troussard. (2019) Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment. American Journal of Hematology 94:12, pages 1413-1422.
Crossref
Amber C. King, Charlene C. Kabel, Jeremy J. Pappacena, Sarah E. Stump & Ryan J. Daley. (2019) No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant. Annals of Pharmacotherapy 53:9, pages 922-932.
Crossref
Jan‐Paul Bohn, Andreas Pircher, David Wanner, David Vill, Bernhard Foeger, Dominik Wolf & Michael Steurer. (2019) Low‐dose vemurafenib in hairy cell leukemia patients with active infection. American Journal of Hematology 94:6.
Crossref
Yazan F. Madanat, Lisa Rybicki, Tomas Radivoyevitch, Deepa Jagadeesh, Robert Dean, Brad Pohlman, Matt Kalaycio, Mikkael A. Sekeres, Mitchell R. Smith & Brian T. Hill. (2017) Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population. Clinical Lymphoma Myeloma and Leukemia 17:12, pages 857-862.
Crossref
Victoria Divino, Sudeep Karve, Andrew Gaughan, Mitch DeKoven, Guozhi Gao, Kevin B Knopf & Mark C Lanasa. (2017) Characteristics and treatment patterns among US patients with hairy cell leukemia: a retrospective claims analysis. Journal of Comparative Effectiveness Research 6:6, pages 497-508.
Crossref
L S Al-radi, T N Moiseeva, S Yu Smirnova & R G Shmakov. (2017) Hairy cell leukemia and pregnancy. Terapevticheskii arkhiv 89:7, pages 99-104.
Crossref
Martina Sollini, Sara Galimberti, Roberto Boni & Paola Anna Erba. 2017. Nuclear Oncology. Nuclear Oncology 1157 1195 .
Dai Chihara, Hagop Kantarjian, Susan O'Brien, Jeffrey Jorgensen, Sherry Pierce, Stefan Faderl, Alessandra Ferrajoli, Rebecca Poku, Preetesh Jain, Phillip Thompson, Mark Brandt, Rajyalakshmi Luthra, Jan Burger, Michael Keating & Farhad Ravandi. (2016) Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. British Journal of Haematology 174:5, pages 760-766.
Crossref
Dharmendra Jain, Pranav Dorwal, Smeeta Gajendra, Amit Pande, Simmi Mehra & Ritesh Sachdev. (2016) CD5 positive hairy cell leukemia: A rare case report with brief review of literature. Cytometry Part B: Clinical Cytometry 90:5, pages 467-472.
Crossref
Sascha DietrichAndreas PircherVolker EndrisFrédéric PeyradeClemens-Martin WendtnerGeorge A. FollowsJennifer HülleinAlexander JethwaElena EllertTatjana WaltherXiyang LiuMartin J. S. DyerThomas ElterTilman BrummerRobert ZeiserMichael HermannMichael HeroldWilko WeichertClaire DeardenTorsten HaferlachMartina Seiffert, Michael HallekChristof von KalleAnthony D. HoAnita Gaehler, Mindaugas AndrulisMichael SteurerThorsten Zenz. (2016) BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Blood 127:23, pages 2847-2855.
Crossref
Erin Streu. (2016) Hairy Cell Leukemia and Bone Pain. Oncology Nursing Forum 43:1, pages 18-21.
Crossref
Martina Sollini, Sara Galimberti, Roberto Boni & Paola Anna Erba. 2016. Nuclear Oncology. Nuclear Oncology 1 39 .
Leslie A. Andritsos & Michael R. Grever. (2015) Historical overview of hairy cell leukemia. Best Practice & Research Clinical Haematology 28:4, pages 166-174.
Crossref
Farhad Ravandi. (2015) Chemoimmunotherapy for hairy cell leukemia. Best Practice & Research Clinical Haematology 28:4, pages 230-235.
Crossref
Monica Else, Claire E. Dearden & Daniel Catovsky. (2015) Long-term follow-up after purine analogue therapy in hairy cell leukaemia. Best Practice & Research Clinical Haematology 28:4, pages 217-229.
Crossref
Sibel Hacioglu, Yusuf Bilen, Ali Eser, Serdar Sivgin, Emel Gurkan, Rahsan Yildirim, Ismet Aydogdu, Mehmet Hilmi Dogu, Mehmet Yilmaz, Omur Kayikci, Anil Tombak, Irfan Kuku, Harika Celebi, Meltem Olga Akay, Ramazan Esen, Serdal Korkmaz & Ali Keskin. (2015) Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapy. Hematological Oncology 33:4, pages 192-198.
Crossref
T. Robak, E. Matutes, D. Catovsky, P.L. Zinzani & C. Buske. (2015) Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 26, pages v100-v107.
Crossref
S. Dietrich, M. Andrulis & T. Zenz. (2015) HaarzellleukämieHairy cell leukemia. Der Internist 56:4, pages 381-390.
Crossref
Pier Luigi Zinzani, Vittorio Stefoni, Alessandro Broccoli, Cinzia Pellegrini, Letizia Gandolfi, Beatrice Casadei, Roberto Maglie, Stefano Pileri & Lisa Argnani. (2014) Is it really possible to cure hairy cell leukemia patients only with frontline therapy?. Annals of Hematology 93:9, pages 1565-1569.
Crossref
Edouard Cornet, C?cile Tomowiak, Aline Tanguy-Schmidt, St?phane Lepretre, Jehan Dupuis, Pierre Feugier, Alain Devidas, Clara Mariette, V?ronique Leblond, Catherine Thi?blemont, Patricia Validire-Charpy, Laurent Sutton, Emmanuel Gyan, Jean-Claude Eisenmann, Pascale Cony-Makhoul, Lo?c Ysebaert & Xavier Troussard. (2014) Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia. British Journal of Haematology 166:3, pages 390-400.
Crossref
V Maevis, U Mey, G Schmidt-Wolf & I G H Schmidt-Wolf. (2014) Hairy cell leukemia: short review, today’s recommendations and outlook. Blood Cancer Journal 4:2, pages e184-e184.
Crossref
Ewelina Wawryk-Gawda, Patrycja Chylińska-Wrzos, Marta Lis-Sochocka, Kamila Bulak & Barbara Jodłowska-Jędrych. (2014) Intrinsic Apoptosis Pathway in Fallopian Tube Epithelial Cells Induced by Cladribine. The Scientific World Journal 2014, pages 1-9.
Crossref
Jae H. Park & Martin S. Tallman. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology 1979 1990.e4 .
Sascha Dietrich, Jennifer Hüllein, Michael Hundemer, Nicola Lehners, Alexander Jethwa, David Capper, Till Acker, Boyan K. Garvalov, Mindaugas Andrulis, Carolin Blume, Christoph Schulte, Thomas Mandel, Julia Meissner, Stefan Fröhling, Christof von Kalle, Hanno Glimm, Anthony D. Ho & Thorsten Zenz. (2013) Continued Response Off Treatment After BRAF Inhibition in Refractory Hairy Cell Leukemia. Journal of Clinical Oncology 31:19, pages e300-e303.
Crossref
Gail Jones, Nilima Parry-Jones, Bridget Wilkins, Monica Else & Daniel Catovsky. (2012) Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*. British Journal of Haematology 156:2, pages 186-195.
Crossref
Amélie Lansiaux. (2011) Les antimétabolites. Bulletin du Cancer 98:11, pages 1263-1274.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.